In a win for three generic drug companies, the U.S. Court of Appeals for the Federal Circuit has invalidated key claims in Bayer AG's patent on the brand-name oral contraceptive Yaz.
April 18, 2013 at 12:00 AM
1 minute read
In a win for three generic drug companies, the U.S. Court of Appeals for the Federal Circuit has invalidated key claims in Bayer AG’s patent on the brand-name oral contraceptive Yaz.
In a 14-page decision issued on Tuesday, the Federal Circuit ruled that the hormone formulation in Yaz was obvious to scientists at the time. Generic drug companies Actavis Inc., Sandoz Inc. and Lupin Ltd. had challenged Bayer’s patent through Hatch-Waxman Act litigation.
Presented by BigVoodoo
The Daily Report is honoring those attorneys and judges who have made a remarkable difference in the legal profession.
Join the industry's top owners, investors, developers, brokers & financiers at THE MULTIFAMILY EVENT OF THE YEAR!
Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.
Atlanta s John Marshall Law School is seeking to hire one or more full-time, visiting Legal WritingInstructors to teach Legal Research, Anal...
Lower Manhattan firm seeks a premises liability litigator (i.e., depositions, SJ motions, and/or trials) with at least 3-6 years of experien...
Join the Mendocino County District Attorney s Office and work in Mendocino County home to redwoods, vineyards and picturesque coastline. ...
MELICK & PORTER, LLP PROMOTES CONNECTICUT PARTNERS HOLLY ROGERS, STEVEN BANKS, and ALEXANDER AHRENS
